PURPOSE: Small cell carcinoma of the urinary bladder (SCCB) is known for its aggressive clinical features and poor prognosis. No prognostic factor has been established so far. The aim of this study was to assess the significance of possible prognostic factors, including serum neuron-specific enolase (NSE), an established biomarker for small cell lung carcinoma. METHODS: We retrospectively reviewed 31 patients with primary SCCB treated at our eight affiliate institutions between 2001 and 2014. The association of various clinicopathological factors at diagnosis, including the serum NSE value, with cancer-specific survival (CSS) was assessed. The log-rank test and Cox proportional hazards model were used for univariate and multivariate analyses, respectively. RESULTS: Nineteen (61.3 %) died of SCCB during the follow-up, with a median survival time of 12.7 months. Prognostic factors were analyzed for the 25 patients after excluding six with missing data. Univariate analysis demonstrated that stage (extensive disease) and serum NSE ≥25 ng/ml were significantly associated with worse CSS. Multivariate analysis identified increased serum NSE value as a sole independent predictor of CSS (hazard ratio 18.52, p = 0.0022). CONCLUSIONS: Serum NSE value at diagnosis was an independent prognostic factor for primary SCCB and may serve as a useful biomarker in the management of SCCB.
PURPOSE: Small cell carcinoma of the urinary bladder (SCCB) is known for its aggressive clinical features and poor prognosis. No prognostic factor has been established so far. The aim of this study was to assess the significance of possible prognostic factors, including serum neuron-specific enolase (NSE), an established biomarker for small cell lung carcinoma. METHODS: We retrospectively reviewed 31 patients with primary SCCB treated at our eight affiliate institutions between 2001 and 2014. The association of various clinicopathological factors at diagnosis, including the serum NSE value, with cancer-specific survival (CSS) was assessed. The log-rank test and Cox proportional hazards model were used for univariate and multivariate analyses, respectively. RESULTS: Nineteen (61.3 %) died of SCCB during the follow-up, with a median survival time of 12.7 months. Prognostic factors were analyzed for the 25 patients after excluding six with missing data. Univariate analysis demonstrated that stage (extensive disease) and serum NSE ≥25 ng/ml were significantly associated with worse CSS. Multivariate analysis identified increased serum NSE value as a sole independent predictor of CSS (hazard ratio 18.52, p = 0.0022). CONCLUSIONS: Serum NSE value at diagnosis was an independent prognostic factor for primary SCCB and may serve as a useful biomarker in the management of SCCB.
Entities:
Keywords:
Bladder cancer; Neuron-specific enolase; Small cell cancer; Small cell carcinoma; Urothelial
Authors: D J Grignon; J Y Ro; A G Ayala; D T Shum; N G Ordóñez; C J Logothetis; D E Johnson; B Mackay Journal: Cancer Date: 1992-01-15 Impact factor: 6.860
Authors: Sanjay G Patel; C J Stimson; Harras B Zaid; Matthew J Resnick; Michael S Cookson; Daniel A Barocas; Sam S Chang Journal: J Urol Date: 2013-09-12 Impact factor: 7.450
Authors: Arlene O Siefker-Radtke; Ashish M Kamat; H Barton Grossman; Dallas L Williams; Wei Qiao; Peter F Thall; Colin P Dinney; Randall E Millikan Journal: J Clin Oncol Date: 2009-05-04 Impact factor: 44.544
Authors: L G Jørgensen; K Osterlind; J Genollá; S A Gomm; J R Hernández; P W Johnson; J Løber; T A Splinter; M Szturmowicz Journal: Br J Cancer Date: 1996-08 Impact factor: 7.640